Park Avenue Securities LLC Sells 835 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Park Avenue Securities LLC lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,599 shares of the company’s stock after selling 835 shares during the quarter. Park Avenue Securities LLC’s holdings in Teva Pharmaceutical Industries were worth $178,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Thrivent Financial for Lutherans boosted its position in shares of Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after acquiring an additional 699 shares during the period. Townsquare Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after acquiring an additional 812 shares during the period. Metis Global Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after acquiring an additional 860 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after acquiring an additional 949 shares during the period. Finally, Blair William & Co. IL boosted its position in shares of Teva Pharmaceutical Industries by 9.4% in the fourth quarter. Blair William & Co. IL now owns 11,232 shares of the company’s stock valued at $248,000 after acquiring an additional 963 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price objective for the company. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Buy” and a consensus target price of $24.44.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $17.50 on Tuesday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80. The stock has a market cap of $20.07 billion, a P/E ratio of -12.07, a PEG ratio of 1.44 and a beta of 0.60. The business has a fifty day moving average of $16.12 and a 200 day moving average of $17.43. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business posted $0.48 earnings per share. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president now owns 9,989 shares of the company’s stock, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.